NCT04162340 - CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 11, 2019

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions

T Cell Lymphoma in RelapseRefractory T-Cell Lymphoma

Interventions

BIOLOGICAL

CD4 CAR T cells

CD4 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.

Trial Locations (2)

RECRUITING

Peking University Shenzhen Hospital, Shenzhen

NOT_YET_RECRUITING

Chengdu Military General Hospital, Chengdu